Delivery Order SPE2DB22D3004-SPE2DB25FRU57
- Not listed
- The Defense Logistics Agency awarded a $1,295.97 delivery order to AmerisourceBergen Drug Corp for Ketorolac 30 mg/ml vials under a firm fixed-price contract structure. The award was issued on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation. This award represents a child contract executed under...
- The Defense Logistics Agency awarded a $1,454.70 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ketorolac 30 mg/mL vials. This is a firm fixed-price contract with no set-aside designation, reflecting competitive procurement on open terms. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $2,605.10 to AmerisourceBergen Drug Corp for the supply of Ketorolac 30 mg/ml vials. This firm fixed-price delivery order, issued on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a non-competitive, non-set-aside procurement of this pharmaceutical product. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,357.72 firm fixed-price delivery order is for the supply of Ketorolac 30 mg/mL vials, a medication used for pain management. The contract has an ultimate completion date of February 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ketorolac 30 mg/mL vials with a ceiling value of $1,163.76. The contract is firm fixed price and is classified as a non-set-aside award, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $15,961.88 by the Medical Supply Chain, a defense-focused federal agency, for the supply of Ketorolac 30 mg/mL vials. This firm fixed price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Ketorolac is a nonsteroidal anti-inflammatory drug commonly used for pain management...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Ketorolac 10 mg tablets (100-count units) valued at $1,182.51. This firm fixed-price delivery order, issued on July 31, 2025, represents a non-set-aside award under open competition and is scheduled for completion by August 1, 2025. The contract will be performed at AmerisourceBergen's corporate office location...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,299.44 firm fixed-price delivery order is for the supply of Ketorolac 30 mg/ml vials, a pain management medication. The contract has a completion date of November 7, 2024 and was awarded on November 6, 2024. This award is a part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $3,886.39 to AmerisourceBergen Drug Corp for the supply of Ketorolac 60 mg/2 mL vials on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ketorolac is a nonsteroidal anti-inflammatory drug commonly used in military and federal...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Ketorolac 15 mg/ml vials. The $6,080.91 firm fixed-price contract has a completion date of November 8, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical for providing a wide range of pharmaceutical products and medical supplies to support military healthcare programs...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRU57Delivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ketorolac 30 mg/mL vials, with a ceiling value of $3,879.20. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating open competitive award. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. This specific award for Ketorolac, a nonsteroidal anti-inflammatory pain management medication, aligns with the company's established role as a primary pharmaceutical supplier to the Defense Health Agency and other federal healthcare entities through the DLA's global pharmaceutical support program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 8/1/25 |